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This article highlights trends in heart and lung trans-
plantation between 1997 and 2006, drawing on data
from the OPTN and SRTR. The total number of candi-
dates actively awaiting heart transplantation declined
by 45% over the last decade, dropping from 2414 pa-
tients in 1997 to 1327 patients in 2006. The overall
death rates among patients awaiting heart transplan-
tation declined over the same period. The distribution
of recipients among the different status groups at the
time of heart transplantation changed little between
the inception of the new classification system in 1999
and 2005. Deaths in the first year after heart transplan-
tation have steadily decreased. At the end of 2006, 2885
candidates were awaiting a lung transplant, up 10%
from the 1997 count. The median time-to-transplant
for listed patients decreased by 87% over the decade,
dropping from 1053 days in 1997 to 132 days in 2006.
Selection for listing and transplantation has shifted
toward more urgent patients since the May 2005 im-
plementation of a new lung allocation system based
on survival benefit and urgency rather than waiting
time. Only 31 heart-lung transplants were performed
in 2006, down from a high of 62 in 1997.
Key words: Graft survival, heart transplantation, lung
transplantation, OPTN, patient survival, SRTR
Introduction
This article reviews recent trends in heart and lung trans-
plantation in the United States. The data reported here
are drawn from the 2007 OPTN/SRTR Annual Report, and
cover all aspects of thoracic organ transplantation in the
last decade. Two recent changes in the allocation systems
for these two organs—the Lung Allocation Score system,
introduced in May 2005, and the increased geographic
sharing of hearts, introduced in July 2006—seem to be
having noticeable effects on transplantation trends. Both
systems were introduced in order to save lives. The data
available for evaluating the beneficial effects of these al-
location changes are not yet quite mature, but interesting
trends are becoming apparent, as described throughout
this article. Critics have challenged some of the early data
interpretation of these changes, as preliminary analyses
(like the statistical models behind the changes themselves)
were based on 1-year risk of patient death, rather than
longer-term risk. Five-year survival rates were not used to
develop these allocation systems, but they will be valuable
when they become available. Revisions in both allocation
schemes are ongoing, as factors are identified that may
enhance the systems’ ability to make the best use of this
scarce resource.
Heart
Heart waiting list characteristics
The characteristics of heart transplant candidates are de-
rived from potential transplant recipients actively awaiting
heart transplantation at the end of each calendar year from
1997 to 2006. Overall, the total number of active candi-
dates declined by 45% over the decade, dropping from
2414 patients in 1997 to 1327 patients in 2006.
The percentage of patients actively awaiting heart trans-
plantation with blood type O increased by approximately
9% over the last 10 years. Other characteristics of heart
transplant candidates, including country of residence, his-
tory of previous transplant with any organ or history of
previous heart or lung transplant, remained relatively un-
changed (≤2% change) from 1997 to 2006.
Patients awaiting heart transplantation are assigned a level
of urgency based on medical condition and include, from
most to least urgent: Status 1A, Status 1B and Status 2. A
Status 1A candidate has either mechanical circulatory sup-
port for acute hemodynamic decompensation, mechani-
cal circulatory support with objective medical evidence of
device-related complications, continuous mechanical ven-
tilation or intra-aortic balloon pump, or continuous infusion
of intravenous inotropes along with continuous monitor-
ing of left ventricular filling pressures. Additionally, a pa-
tient may be listed as Status 1A in the absence of these
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Source: 2007 OPTN/SRTR Annual Report, Table 11.1a.
Figure 1: Status of heart transplant waiting list, 2000–2006.
for Status 1A to the Regional Review Board and the appli-
cation is approved. The decision of the Regional Review
Board is also reviewed by the OPTN Thoracic Organ Trans-
plantation Committee if the assessment of the Regional
Review Board is appealed by the transplant center. Status
1B covers candidates with a left or right ventricular assist
device implanted and candidates receiving a continuous
infusion of intravenous inotropes without the specific re-
quirement of continuous monitoring of left ventricular fill-
ing pressures. A candidate not meeting the conditions for
Status 1A or Status 1B may be listed as Status 2. Most
candidates for heart transplantation are listed as Status
2; this has consistently been the case since 1997. Since
1999, there has been a 51% decrease in number of pa-
tients listed as Status 2, an 18% decrease in number of
patients listed as Status 1B and a 14% decrease in pa-
tients listed as Status 1A. These changes have resulted
in a relative increase in the proportion of candidates listed
at Status 1A or 1B. The proportion of patients listed at
each Status has remained relatively constant since 2004
(Figure 1).
Overall, the distribution of time spent on the heart trans-
plant waiting list did not change appreciably from 1997
to 2006, although there was a small increase (approxi-
mately 6%) in the percentage of patients awaiting heart
transplantation for two or more years. This increase was
seen primarily in the type O blood group; while there was a
slight decrease in type A, type B and AB were virtually un-
changed. Of the 78 patients awaiting heart transplantation
and listed as Status 1A as of January 1, 2006, 27%, 17%
and 14% of patients remained listed as Status 1A at the
end of 30, 60 and 90 days, respectively. The percentages
of patients initially listed at Status 1A who received a heart
transplant were 37%, 54% and 58% at 30, 60 and 90 days,
respectively. For the 324 patients awaiting transplantation
and listed as Status 1B as of January 1, 2006, 75%, 58%
and 46% remained listed as Status 1B at 30, 60 and 90
days, respectively, while 12%, 24% and 34% of patients
























Source: 2007 OPTN/SRTR Annual Report, Table 11.3.
Figure 2: Annual death rate of patients awaiting heart trans-
plantation, per 1000 patient-years at risk, 1997–2006.
patients listed as Status 2, only 6%, 8% and 11% received
a heart transplant by 30, 60 and 90 days, respectively.
Deaths on the heart waiting list
The overall death rates among patients awaiting heart
transplantation have declined over the last 10 years, from
227 per 1000 patient-years at risk in 1997 to 152 per
1000 patient-years at risk in 2006 (Figure 2). This trend
was clearly evident regardless of ethnicity, sex, blood
type (except blood group AB), age (except for patients
<1 year old) and diagnosis (except for retransplant/graft
failure/unknown). Death rates on the heart waiting list de-
creased sharply among Status 1A candidates, from 2087
deaths per 1000 patient-years at risk in 2000 to 1457 deaths
per 1000 patient-years at risk in 2006 (Figure 3). Death rates
among Status 1B and Status 2 patients declined as well,
though less sharply and with more year-to-year variability
(Figure 3). The increasing prevalence of ventricular assist
device (VAD) placement may have contributed to the de-



























*Data prior to 2000 not shown due to change in status categories
Source: 2007 OPTN/SRTR Annual Report, Table 11.3.
Figure 3: Annual death rates per 1000 patient-years on the
heart waiting list by status, 2000–2006.
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Heart transplant recipient characteristics
The overall number of heart transplants performed has var-
ied by 14% over the past decade, from a high of 2348 in
1998 to a low of 2015 in 2004. After reaching a 10-year
low in 2004, the number of transplants increased slightly
in each of the past 2 years. There was also a 14% de-
crease in the rate of heart transplants per million US resi-
dents over the last 10 years, though this trend appears to
have leveled off over the last few years (Figure 4). Among
patients transplanted, there has been an 18% decrease
in the 50–64 age group, a 19% reduction in the number
of white recipients and a 24% reduction in the number of
patients transplanted with a diagnosis of coronary artery
disease. As with changes in waiting list characteristics,
these changes have resulted in greater percentages of pa-
tients receiving transplants among younger age groups,
nonwhites and candidates with a diagnosis other than coro-
nary artery disease. Other important trends have included a
51% reduction in the number of patients hospitalized in an
intensive care unit before heart transplantation and a recip-
rocal increase in the number of patients hospitalized out-
side an intensive care unit or not hospitalized at all before
heart transplantation. There has also been a 17% reduction
in the number of patients on life support (extracorpo-
real membrane oxygenation, intra-aortic balloon pump,
prostaglandins, intravenous inotropes, inhaled nitric oxide,
ventilator) at the time of heart transplantation over the
past decade. There have been no significant changes in
the characteristics of heart transplant recipients with re-
spect to sex (approximately 75% of heart recipients are
male), recipient blood type, previous transplant with any
organ, previous heart or heart-lung transplant and recipient
residency.
The distribution of patients among the different status
groups on the waiting list at the time of heart transplan-
tation changed little between the inception of the new
classification system in 1999 and 2005. At that time pa-
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Source: 2007 OPTN/SRTR Annual Report, Tables 11.4 and 11.5.
Figure 4: Number of heart transplants and incidence of trans-
plant per million population, 1997–2006.
tation comprised approximately 40%, 35% and 25%, of
the entire cohort. However, in 2006 the proportion of Sta-
tus 2 patients dropped to 20%, while Status 1A and 1B
patients increased to 42% and 38%, respectively (Fig-
ure 5). This change is likely attributable to the wider ge-
ographic sharing of donor hearts for candidates at Status
1A or 1B as a result of the change in donor heart alloca-
tion process approved by the OPTN Board of Directors in
November 2005 and implemented in July 2006 (1). The
policy was expected to lead to a decrease in Status 2
transplants in favor of candidates listed at a more urgent
status. Despite an increase in the geographic sharing of
donor hearts for candidates at Status 1A or 1B, there was
only a 1% increase in the number of donor organs with
cold ischemic time between 270–360 min from 2005 to
2006 compared to earlier years. Other cold ischemic time
categories had even less of an increase or no increase
at all.
Immunosuppression therapy for heart transplantation
The immunosuppression regimen for heart transplant re-
cipients has continued to evolve over the past decade.
Induction therapy in the form of Atgam (equine antithy-
mocyte globulin) or OKT3 (muromonab-CD3) was used
for 30% of patients in 1997. While use of induction
therapy has gradually increased, reaching 57% in 2006,
both Atgam and OKT3 have been largely replaced by
the use of Thymoglobulin (rabbit anti-lymphocyte globu-
lin) or monoclonal antibody therapy directed against the
IL-2 receptor—namely, Zenapax (daclizumab) or Simulect
(basiliximab). Over the past decade, the overwhelm-
ing majority (approximately 80%) of transplant recipi-
ents were discharged on triple drug therapy consist-
ing of a calcineurin antagonist, mycophenolate mofetil
(MMF)/myocophenolic acid (MPA) or other antimetabolite,
and steroid therapy. The two most common regimens
in 1997 (75% of transplant recipients) were cyclosporine
(CyA) with either mycophenolate mofetil/myocophenolic
acid or another antimetabolite and steroids. These com-
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Source: 2007 OPTN/SRTR Annual Report, Table 11.4.
Figure 5: Status of heart transplant recipients, 2000–2006.

























Source: 2007 OPTN/SRTR Annual Report, Table 11.7.
Figure 6: Annual death rate per 1000 patient-years at risk, for
recipients during first year after heart transplantation, 1997–
2005.
mycophenolate mofetil/myocophenolic acid and steroids
(49% of transplant recipients)—and, to a lesser extent
(29% of transplant recipients), cyclosporine, mycopheno-
late mofetil/myocophenolic acid and steroids. At 1 year
following transplantation, triple drug therapy with a cal-
cineurin antagonist (principally tacrolimus), mycophenolate
mofetil/myocophenolic acid and steroid therapy remains
the predominant treatment regimen. However, since 1997
there has been a small (approximately 15% of patients)
but important trend toward steroid-free drug regimens
by 1 year following transplantation. Heart transplant re-
cipients discharged on tacrolimus and mycophenolate
mofetil/myocophenolic acid, with or without steroid ther-
apy, have the greatest likelihood of remaining on this drug
regimen, compared to all other drug combinations at 3
years following transplantation. A notable trend is the de-
clining number of recipients who needed treatment for
rejection episodes during the first year following transplan-
tation (25% in 2005 compared to 36% in 1996). An over-
whelming majority of patients were treated with steroid























Source: 2007 OPTN/SRTR Annual Report, Table 11.13.
Figure 7: Adjusted short- and long-term survival of heart re-
cipients, by year of transplant, 1994–2005.
form of antibody therapy. The decline probably reflects
the improved efficacy of the newer immunosuppression
medications, but also may result from incremental im-
provements in the overall care of donors and recipients.
The incidence of infection and malignancy require further
analysis to identify meaningful trends.
Heart transplant outcomes
Deaths in the first year after heart transplantation have
steadily decreased from 171 deaths per 1000 patient-years
at risk in 1997 to 132 deaths per 1000 patient-years at risk
in 2003 (Figure 6). There has been a slight increase in the
incidence of death during the last 2 years, to 142 deaths
per 1000 patient-years at risk. Adjusted to the characteris-
tics of the 1996 heart transplant population (age, sex, race
and diagnosis), patient survival at 3 months and 1 year im-
proved from 89.7 ± 0.6% and 85.2 ± 0.7%, respectively,
in 1996, to 92.1 ± 0.6% and 87.8 ± 0.7%, respectively, in
2005. Long-term survival at 3 and 5 years increased from
77.3 ± 0.9% and 70.8 ± 1.0%, respectively, in 1996, to
79.2 ± 0.9% and 73.7 ± 1.0% in 2001, the most recent
year with adequate posttransplant follow-up (Figure 7). Ad-
justed graft survival was nearly identical to adjusted patient
survival. The prevalence of people living with a functioning
heart allograft at year end increased every year from 13 829
in 1997 to 18 018 in 2005.
There has been variability in how posttransplant death
rates have declined since 1997. The downward trajectory
of 1-year death rates was more marked among African
Americans and Hispanics and has brought them more
into line with the 1-year death rates of whites. African
Americans experienced somewhat worse survival starting
at 3 years after transplantation relative to other ethnicity
groups. Downward trends in death rates have had more
year-to-year variability among the smaller number of Asian
transplant recipients (Figure 8). Death rates for females and
males were similar in 2005, though females generally have
had a higher death rate over the last 10 years.
Congenital heart disease patients have seen worse post-
transplant survival than have patients with coronary artery
disease, valvular heart disease or cardiomyopathy. In gen-
eral, there has been a decline in death rates among all
status groups since 1999; however, in 2005 there was
an increase over 2004 rates in both Status 1A and Status
2 groups. Status 1B experienced a sharp decrease in 2005
compared to 2004 (Figure 9). In 2005, annual death rates
per 1000 patient-years at risk during the first year after
transplantation remained highest for those 1–5 years old or
those 65 years or older, with death rates of 245 and 176, re-
spectively. A 1-year death rate of 63 per 1000 patient-years
at risk set a new 10-year low for patients aged 11–17 years
in 2004, but this rate returned to 172 in 2005, reflecting the
year-to-year variability witnessed in this group over the last
decade. By diagnosis from highest to lowest, the death
rates in 2005 were 323 for congenital heart disease, 143
980 American Journal of Transplantation 2008; 8 (Part 2): 977–987
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Source: 2007 OPTN/SRTR Annual Report, Table 11.7.
Figure 8: Annual death rates per 1000 patient-years during
first year following heart transplantation by race/ethnicity,
2001–2005.
for coronary artery disease, 112 for cardiomyopathy and
105 for valvular heart disease.
Heart allocation policy changes
In July 2006, the OPTN Thoracic Organ Transplantation
Committee implemented an allocation policy change mov-
ing Zone A 1A and 1B patients ahead of local Status 2 pa-
tients (1). It is predicted that the policy change will result
in fewer deaths on the waiting list and overall. However,
very little follow-up has yet been accrued, even for those
patients transplanted earliest during the era affected by the
policy change. While some impact from the policy change
may be reflected in the trends described above, it is ex-
pected that a more comprehensive review of the new pol-
icy’s effect can be made in future reports, after sufficient
numbers of patients have received transplants under the
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Source: 2007 OPTN/SRTR Annual Report, Table 11.7.
Figure 9: Annual death rate per 1000 patient-years at risk,























Source: 2007 OPTN/SRTR Annual Report, Tables 1.3 and 12.1a.
Figure 10: Active versus inactive lung waiting list patients at
year-end, 1997–2006.
Lung
The lung transplantation section of this article is organized
differently than the heart section because policy changes
following the institution of the Lung Allocation Score (LAS)
system are most logically reviewed in terms of deaths
on the waiting list and following transplantation. Rather
than a discussion of waiting list characteristics and out-
comes followed by a discussion of transplant recipient
characteristics and outcomes, the discussion of waiting list
and transplant characteristics and outcomes is combined.
Lung: Overview
At the end of 2006, 2885 candidates were registered on the
lung waiting list and awaiting a transplant. This figure repre-
sents a 9% drop from the 2005 count of 3156, following an
18% drop from 3866 in 2004. The change between 2005
and 2006 is almost entirely due to a decrease in the number
of inactive registrants, as the number of registrants active
on the lung waiting list remained steady between 2005






















Median Time to Transplant
*Median not determined in 1999 because fewer 
than 50% of patients received a transplant.
*
Source: 2007 OPTN/SRTR Annual Report, Table 12.2.
Figure 11: Time to transplant for new lung waiting list regis-
trations, 1997–2006.
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patients in 2004 (Figure 10). Many of the sections below
describe year-over-year trends and changes from 2005 to
2006; it is also important to note that many of these trends
(for instance, the waiting list numbers described above)
were relatively stable for the previous decade, and under-
went a pronounced change upon the introduction of the
LAS system in May 2005.
The percentage of actively listed patients waiting less than
6 months for a transplant was 42% at the end of 2006,
as opposed to only 32% of patients at the end of 2004,
although the number of patients waiting less than a year
was roughly 55% in each case. The number of patients
waiting more than 1 year for a transplant dropped substan-
tially from 967 in 2004 to 452 in 2006 (a 53% decrease).
The median time-to-transplant for listed patients decreased
by 87% over the decade, dropping from 1053 days in 1997
to 132 days in 2006 (Figure 11). Most of this decrease was
seen between 2004 and 2006. In 2006, 10% of wait-listed
patients received an organ within 9 days of being listed and
25% of listed patients received an organ within 31 days of
listing.
The waiting list death rate dropped by 48% between 1997
and 2006, from 185 to 97 deaths per 1000 patient-years
at risk (Figure 12). Forty-three percent of this decrease oc-
curred between 2004 and 2006 (135 to 97 deaths per 1000
patient-years at risk). The smaller number of candidates,
shorter accrued waiting times and markedly reduced death
rates on the waiting list between 2004 and 2006 are likely
to be attributable in large part to the recent change in the
lung allocation policy. Selection for listing and transplanta-
tion has shifted toward more urgent patients since imple-
mentation in May 2005 of the LAS system, which is based
on survival benefit and urgency rather than waiting time (2).
In addition, the Organ Donation Breakthrough Collaborative
has helped organize efforts toward increasing the pool of
































Source: 2007 OPTN/SRTR Annual Report, Table 12.3.
Figure 12: Annual death rate of patients on the lung waiting






















Source: 2007 OPTN/SRTR Annual Report, Table 12.4.
Figure 13: Number of deceased donor lung transplants, 1997–
2006.
ceased donor lung transplants increased by 54% over the
past decade, from 910 in 1997 to 1401 in 2006. Roughly
half of this increase was seen between 2004 and 2005;
the number changed little between 2005 and 2006 (Figure
13). The use of DCD lung transplants remains uncommon
but increased from 3 in 2003 to 11 in 2006.
The reduced death rates on the waiting list since 2004
were offset by increased death rates observed between
2004 and 2005 in the first year after transplant with a
deceased donor lung, likely a consequence of select-
ing more urgent patients for transplantation. The average
death rate in the first year after transplantation decreased
steadily from 290 per 1000 patient-years at risk in 1997 to
169 deaths per 1000 patient-years at risk in 2004, a 10-
year low. The death rate in the first year following trans-
plantation rose back up to 200 per 1000 patient-years at risk
(Figure 14) for transplants occurring during 2005. However,
despite the increase in the 1-year posttransplant death rate
for 2005, the total number of deaths on the waiting list




































Source: 2007 OPTN/SRTR Annual Report, Table 12.7a.
Figure 14: Annual death rates per 1000 patient-years at risk
during first year after deceased donor lung transplant, 1997–
2005.
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* Adjusted to characteristics of transplants in 1996. Values past 2001 for 5-year, 2003 for 3-
year, and 1996 for 10-year survival not determined due to insufficient follow-up. 
Source: 2007 OPTN/SRTR Annual Report, Table 12.13a.
Figure 15: Adjusted short- and long-term deceased donor
lung patient survival, by year of transplant, 1994–2005.
deaths in 2004 to 1147 in 2005. (Here, and in subanaly-
ses below, the total number of deaths includes all deaths
after transplant during the year, regardless of when the
transplant occurred.) Taken in combination, the net gain
was 5.5 deaths prevented per 1000 patient-years at risk.
It remains to be seen whether this pattern will continue
and how long-term death rates may alter the picture of net
gain. The increases in posttransplant death rates between
2004 and 2005 can likely attributed to sicker patients being
selected for transplant during these years. It should also be
noted that the total number of deaths presented here do
not account for patients who may have been removed from
the list because they were too ill to receive a transplant and
who subsequently died. Since May 2005 more acutely ill
patients have been listed for transplantation, and it is prob-
able that some are indeed removed from the waiting list
and die shortly thereafter. Consequently, a composite risk
of death for all patients may not be completely captured by
the data presented here.
Once adjusted for age, race, sex and diagnostic character-
istics of the 1996 transplant cohort, posttransplant patient
survival rates were comparable to those seen in previous
years, 92% at 3 months and 84% at 1 year (Figure 15). (It is
important to note that disease severity was not adjusted for
in these comparisons, as much more information is avail-
able now than was available in 1996.) Three-year survival
rates for these patients will not be available for another
2 years.
Lung: Breakdown by age
The age distribution of active patients on the lung waiting
list has changed over the past decade (Figure 16). The per-
centage of patients 50 and older increased from 44% in
1997 to 60% in 2006. The percentage of patients 18–49
decreased from 50% in 1997 to 36% in 2006, and the per-
centage of patients 11–17 decreased from 4% to 2%. With
the exception of the shift in the percentage of adolescents
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Source: 2007 OPTN/SRTR Annual Report, Table 12.1a.
Figure 16: Age distribution of active lung waiting list at year-
end, 1997–2006.
2004 and 2006, most of these distributional shifts were al-
ready occurring during the 8 years before implementation
of the new lung allocation policy. These trends in chang-
ing age distribution simply continued between 2004 and
2006.
Although there were only relatively small shifts in the age
distribution of patients on the waiting list between 2004
and 2005, the absolute numbers of patients decreased by
at least 50% in all but the youngest and oldest age groups.
The number of patients aged 65 years and above and those
aged 6–10 years also decreased but by only 21% and 36%,
respectively. The numbers of patients on the waiting list
remained fairly steady between 2005 and 2006 for patients
aged 18 to 64 years.
Except for very young children—for whom rates are unsta-
ble because of the small numbers of patients and deaths—
patients aged 65 years and older had the highest waiting
list death rates in 2006, followed by 11- to 17-year-olds
and 50- to 64-year-olds. Candidates aged 18–34 years and
35–49 years had the lowest death rates.
The number of transplants among patients less than
18 years old was fairly constant from 2004 to 2006. Trans-
plants among 18 –49-year-olds increased approximately 9–
10% since 2004. Transplants among patients over the age
of 50 years have more than kept pace with the increases in
the number of wait-listed patients in this age group, with
a 28% increase in transplants since 2004 and a 97% in-
crease since 1997. In 2006, 936 transplants occurred in
patients older than 50 years. The percentage of patients
aged 50–64 receiving transplants has not changed sub-
stantially since 2004, with 55% of deceased donor lungs
going to these patients in 2006, up slightly from 48% in
1997 (Figure 17). However, between 1997 and 2006, the
number of lung transplants in patients over age 65 years
nearly quadrupled (42, 81 and 164 transplants in 1997, 2004
and 2006, respectively). In 2006, patients aged 65 years
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or older represented 12% of all lung transplant recipients
(Figure 17).
Since the implementation of the LAS system, first-year
posttransplant death rates have increased for all age
groups. Since 1997, the highest first-year posttransplant
death rate has generally been seen for recipients 65 years
or older, with 251 deaths per 1000 patient-years at risk for
patients who received a transplant during 2005. First year
posttransplant death rates for patients aged 18–34 years,
35–49 years and 50–64 years decreased until 2004. Again,
there was an increase in the death rates for each of these
age groups in 2005, likely related to more urgent patients
being considered for transplantation.
For all age groups other than 11- to 17-year-olds, the total
numbers of deaths on the waiting list and following trans-
plantation changed little from 2004 to 2005. Between 2004
and 2005, total deaths among patients aged 11–17 years
dropped from 38 to 29, a 24% decrease. The other age
groups experienced smaller changes in total deaths. Total
deaths among patients aged less than 11 years remained
constant, among patients aged 18–34 years dropped by
5%, among patients aged 35–49 years rose by 5%, among
patients aged 50–64 years dropped by 4% and among pa-
tients 65 years and older rose by 6%.
Lung: Breakdown by diagnosis groups
The diagnosis distribution of wait-listed patients changed
noticeably between 2004 and 2006. The most pronounced
shifts were seen in the percentage of patients with idio-
pathic pulmonary fibrosis (IPF), which decreased from 18%
to 14% of listed patients, and the percentage of patients
with chronic obstructive pulmonary disease (COPD), which
increased from 31% to 36% of listed patients (Figure 18).
This change reflects, in part, a relative increase in the num-
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Source: 2007 OPTN/SRTR Annual Report, Table 12.4a.
























Emphysema/COPD          Cystic Fibrosis         
Idiopathic Pulmonary Fibrosis  Alpha-1-Antitrypsin Deficiency              
Primary Pulmonary Hypertension            Retransplant/Graft Failure                 
Congenital Disease      Other/Unknown
Source: 2007 OPTN/SRTR Annual Report, Table 12.1a.
Figure 18: Primary diagnoses of patients active on the lung
waiting list, 1997–2006.
Despite this shift, emphysema and COPD remain the
most common diagnoses leading to transplantation
(Figure 19). At the end of 2006, 435 emphysema/COPD
patients received transplants (31% of all transplants), while
371 continued to wait (36% of candidates); corresponding
percentages for other major diagnoses include the follow-
ing: IPF (29% of transplants, 14% of candidates), cystic
fibrosis (17% of transplants, 15% of candidates) and pri-
mary pulmonary hypertension (2% of transplants, 5% of
candidates). Waiting time has dropped dramatically for all
diagnosis groups since 2004. Although most of the change
occurred between 2004 and 2005, there were further de-
creases in waiting time in 2006, particularly for primary pul-
monary hypertension (PPH) patients, whose waiting times
had been two to seven times longer than other groups in
2004 and 2005. In 2006, PPH patients continued to have
the longest waiting times among these diagnosis groups,
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Source: 2007 OPTN/SRTR Annual Report, Tables 12.1a and 12.4.
Figure 19: Primary diagnosis of patients on the lung waiting
list (WL) and deceased donor lung recipients (Tx), 2004–2006.
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Emphysema/COPD                   Cystic Fibrosis                  
Idiopathic Pulmonary Fibrosis    Alpha-1-Antitrypsin Deficiency   
Primary Pulmonary Hypertension   All
Source: 2007 OPTN/SRTR Annual Report, Table 12.7a.
Figure 20: Annual death rates during first year after deceased
donor lung transplant, by primary diagnosis, 1997–2005.
For all diagnosis groups other than IPF, there were declin-
ing first-year posttransplant death rates until 2004 followed
by increased rates in 2005 (Figure 20); IPF death rates con-
tinued to fall, reaching a 10-year low in 2005, when the LAS
was implemented. Throughout the same decade emphy-
sema/COPD and cystic fibrosis (CF) recipients had similar
death rates, trending lower than patients with other un-
derlying diagnoses. PPH patients had the highest 1-year
posttransplant death rates in 2005, roughly 70–90% higher
than the death rates of the other most common diagnoses
(Figure 20). Fortunately, 5-year adjusted survival is more
comparable for these diagnosis groups (PPH: 51%; CF:
52%; IPF: 51%; emphysema/COPD: 54%).
Between 2004 and 2005, the death rate on the waiting list
decreased for all of the most common diagnosis groups
while the death rate in the first year after transplant in-
creased for all but IPF patients (Figure 21). The total number
of deaths on the waiting list and after transplant (includ-
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Source: 2007 OPTN/SRTR Annual Report, Tables 12.3 and 12.7a.
Figure 21: Death rate for patients on the lung waiting list (WL)
and in the 1st year following deceased donor lung transplant






























Source: 2007 OPTN/SRTR Annual Report, Table 12.4a.
Figure 22: Deceased donor lung transplants by procedure
type, 1997–2006.
of when the transplant occurred), however, decreased for
all of the diagnosis groups. In 2005, total deaths among
PPH patients dropped from 57 to 53 (7%), among CF pa-
tients dropped from 196 to 166 (15%), among IPF pa-
tients dropped from 280 to 258 (8%), and among emphy-
sema/COPD patients dropped from 389 to 370 (5%).
The percentage of patients waiting for a retransplant in-
creased from 3% in 2004 to 4% in 2006, although the
actual number of such candidates decreased from 67 in
2004 to 44 in 2006. In 2005–2006, 128 patients with a
previous lung or heart-lung transplant were retransplanted
with a deceased donor lung, more retransplants than were
performed in the previous 4 years combined. In 2005, 305
deaths per 1000 patient-years were observed among pa-
tients with any previous transplant, a 57% higher death
rate than seen for recipients without previous transplants.
These trends of increasing posttransplant mortality for pa-
tients rejoining the lung waiting list must be monitored
closely. Further analysis of the risk-benefit profile for re-
transplantation and appropriate policy changes in lung allo-
cation scoring should be considered as results emerge.
The number of bilateral lung transplants has more than
doubled over the decade, rising from 432 (48% of de-
ceased donor lung transplants) in 1997 to 897 (64% of
transplants) in 2006 (Figure 22). In 2005, first-year post-
transplant death rates were 7% lower for double lung
recipients than for single lung recipients, although this
comparison does not adjust for multivariate factors such
as diagnosis and age (Figure 23). Because the survival ad-
vantage conferred by a double lung transplant is still un-
clear, further analysis is needed, including the impact on
organ utilization of more double lung transplants being per-
formed. Appropriate use of marginal donor lungs typically
mandates double lung transplantation. Consequently, the
liberal performance of double lung transplantation may not
hinder aggressive and appropriate use of available donor
lungs.































Source: 2007 OPTN/SRTR Annual Report, Table 12.7a.
Figure 23: Annual death rates per 1000 patient years at risk
during first year after deceased donor lung transplant by pro-
cedure type, 1997–2005.
Lung: Breakdown by sex
At the end of 2006 the percentage of waiting females,
62%, was the highest observed in 10 years, up from 55%
at the end of 2004 though up only slightly from 2005. The
percentage of deceased donor lung transplants performed
in females reached a 10-year low in 2006 at 44%, down
from 50% in 2004, but little changed from 2005. Since the
death rate for females on the waiting list has been con-
sistently lower than that for males over the past 10 years,
this distributional change may be a consequence of sicker
patients being selected for transplantation as assessed by
LAS factors and not a sex-related effect.
First-year posttransplant death rates were generally lower
for females than males throughout the decade. Total
deaths on the waiting list and following transplantation de-
creased for females from 2004 (610) to 2005 (600). Total
deaths for males also decreased by 3% for males from
2004 (562) to 2005 (547).
Lung: Breakdown by ethnicity
There has been minimal variation in ethnic makeup of the
active waiting list over the past 10 years. Hispanic pa-
tients had much higher waiting list death rates than whites,
African Americans or Asians in 2006. This higher death rate
cannot be explained by a difference in proportion between
candidates and recipients, as both groups were 5% His-
panic in 2006. The median time-to-transplant was longer for
Hispanic patients (192 days) than for whites (128 days) and
African Americans (132 days), but not Asians (262 days).
Death rates in the first year after lung transplant were
within random variation for Hispanic, white and African-
American patients, although the death rate was lowest for
African Americans. The 2005 death rate for Asian patients
was particularly poor (517 deaths per 1000 patient-years),
but this rate is based on very small numbers. White pa-
tients continue to make up the majority of patients waiting
(86%) and being transplanted (85%).
Immunosuppression therapy after lung
transplantation
Induction therapy was used for 57% of all lung trans-
plants performed in 2006, up from only 22% of lung
transplants in 1997. The induction therapies used most
commonly in 2006 were basiliximab (Simulect) (24%) and
daclizumab (Zenapax) (16%). In 1997, antithymocyte globu-
lin induction therapy (was used for 20% of transplants and
was by far the most common therapy. In 2006, baseline
therapy prior to discharge included corticosteroids (97%),
tacrolimus (Prograf®, Astellas Pharma US, Deerfield, IL)
(83%), and an antimetabolite—either azathioprine (Imuran,
GlaxoWellcome, New Zealand) (39%) or mycophenolate
mofetil (Cellcept, Roche, Nutley, NJ) (52%)). Calcineurin
inhibitor use has changed dramatically—from the predom-
inant use of cyclosporine (Neoral or Sandimmune, Novar-
tis, East Hanover, NJ) (75%) in 1997 to tacrolimus (83%) in
2006. In 2005, maintenance immunosuppression adminis-
tered for the first year following transplantation was essen-
tially the same as immunosuppression before discharge,
except that the use of tacrolimus increased from 76% to
86% and the use of sirolimus increased from 1% to 8%
of lung transplants. The immunosuppressive agents most
commonly used to treat acute rejection within the first year
after transplant were corticosteroids, used in 95% of acute
rejection cases.
Center and donor lung transplant outcomes
Centers with a volume greater than 21 transplants per
year had higher 5-year unadjusted graft and patient survival
rates (53% and 56%, respectively) than did lower-volume
centers (39–48% and 45–51%, respectively). Recipients
of lungs from donors aged 18–34 years had the best un-
adjusted 5-year patient survival rates (56%), aside from re-
cipients from donors <1 (71%, based on small numbers).
Recipients of lungs from donors aged 65 years and above
had the lowest patient survival (47%).
Heart-Lung
After falling steadily from 164 candidates at the end of
1997 to only 45 at the end of 2005, the number of pa-
tients on the active waiting list for a heart-lung transplant
increased slightly in 2006, to 53 patients. These num-
bers are very small compared to the 1327 active heart
waiting list patients and 1032 active lung waiting list pa-
tients. The death rate on the waiting list in 2006 (143 per
1000 patient-years at risk) was significantly lower than it
was in 1997 (284).
Only 31 heart-lung transplants were performed in 2006,
down from a high of 62 in 1997. Nearly half the heart-
lung recipients were aged 35–49 years, and the most
common diagnoses were PPH and congenital heart dis-
ease. There were 54 transplant centers that performed
heart-lung transplants at some point between 1997 and
2006, but only 15 performed a combined transplant
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in 2006. The death rate in the first year following heart-
lung transplantation dropped to a 10-year low in 2006. Ad-
justed patient survival rates at 3 months, 1 year, 3 years and
5 years were, respectively, 83%, 76%, 56% and 49%. The
5-year survival rate of 49% is similar to that of lung trans-
plant recipients, but the short-term and mid-term survival is
much lower than for either heart or lung transplantation.
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